ADVICENNE (ALDVI.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALDVI - FR0013296746 - Common Stock
ALDVI.PA Key Statistics, Chart & Performance
The current stock price of ALDVI.PA is 1.798 EUR. In the past month the price increased by 9.37%. In the past year, price decreased by -13.35%.
ALDVI.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.36 | 209.67B | ||
| SAN.PA | SANOFI | 11.28 | 208.31B | ||
| SNW.DE | SANOFI | 11.28 | 208.31B | ||
| MRK.DE | MERCK KGAA | 13.6 | 50.43B | ||
| UCB.BR | UCB SA | 37.46 | 46.78B | ||
| UNC.DE | UCB SA | 37.17 | 46.41B | ||
| 1BAYN.MI | BAYER AG-REG | 5.75 | 30.17B | ||
| BAYN.DE | BAYER AG-REG | 5.71 | 29.95B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.84 | 10.64B | ||
| IPN.PA | IPSEN | 12.1 | 10.42B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 100.96 | 9.35B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 18.41 | 7.90B |
Related stock screener links
About ALDVI.PA
Company Profile
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Company Info
ADVICENNE
262, Rue du Faubourg Saint Honore
Paris ILE-DE-FRANCE FR
Employees: 21
Phone: 33185733620
ADVICENNE / ALDVI.PA FAQ
What does ADVICENNE do?
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
What is the stock price of ADVICENNE today?
The current stock price of ALDVI.PA is 1.798 EUR. The price increased by 1.12% in the last trading session.
Does ADVICENNE pay dividends?
ALDVI.PA does not pay a dividend.
How is the ChartMill rating for ADVICENNE?
ALDVI.PA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy ALDVI stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALDVI.PA.
What is the market capitalization of ALDVI stock?
ADVICENNE (ALDVI.PA) has a market capitalization of 25.57M EUR. This makes ALDVI.PA a Nano Cap stock.
ALDVI.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALDVI.PA. When comparing the yearly performance of all stocks, ALDVI.PA is one of the better performing stocks in the market, outperforming 81.69% of all stocks.
ALDVI.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALDVI.PA. ALDVI.PA may be in some trouble as it scores bad on both profitability and health.
ALDVI.PA Financial Highlights
Over the last trailing twelve months ALDVI.PA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS increased by 14.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALDVI.PA Forecast & Estimates
9 analysts have analysed ALDVI.PA and the average price target is 4.08 EUR. This implies a price increase of 126.92% is expected in the next year compared to the current price of 1.798.
For the next year, analysts expect an EPS growth of 17.08% and a revenue growth 54.05% for ALDVI.PA